Skip to content
XNCR·Nasdaq·US

Xencor

Xencor is a clinical-stage biotechnology company focused on engineered antibodies and related therapeutic platforms for cancer and autoimmune disease. Its revenue comes primarily from collaboration agreements, technology licensing, milestone payments, and royalties from partnered drug programs.

Thematic Position

XNCR

Relationship Groups

Suppliers1
Partners3
Licensing11
Competitors4

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

16 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tarifftrade policy
China imposes reciprocal tariffs in response to U.S. trade actions
SEC 10-KFeb 25, 2026

The full regulatory passage is part of the Pro plan.

1 more · Regulatory and geopolitical insights are part of the Pro plan.